ClinicalTrials.gg
CompletedNCT02706483IBS-CUpdated Aug 18, 2020Results posted

Long Term Safety Study of Plecanatide

A Phase 3 interventional study of Plecanatide in Irritable Bowel Syndrome, sponsored by Bausch Health Americas, Inc.. Completed at 204 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-08-18.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,272
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Irritable Bowel Syndrome by Bausch Health Companies Inc. — none open to participants now, none under way, none of them phase 3. Irritable Bowel Syndrome · Bausch Health Companies Inc..

Enrollment
Largest of 10
2,272 · median 337
Started
2016
the only one that year
Phase 3
3 of 10
none open now
Registered
9th of 10
by date

Among the 10 studies in Irritable Bowel Syndrome by Bausch Health Companies Inc., this one has the largest enrollment, is the only one that started in 2016, is one of 3 in phase 3, and was the 9th registered.

Irritable Bowel Syndrome

1,119 studies on the registry are indexed under Irritable Bowel Syndrome; 210 are open to participants now.

Browse Irritable Bowel Syndrome studies →

Open to participants now

None of the 10 studies in Irritable Bowel Syndrome by Bausch Health Companies Inc. is open now. The open studies under Irritable Bowel Syndrome, anywhere →

Where they have run

Who these studies take

Of the 129 Irritable Bowel Syndrome studies recruiting now, 34 (26%) set no upper age limit and 85 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Irritable Bowel Syndrome by Bausch Health Companies Inc. as a file.
02

Study summary

Multi-center, open-label, long-term safety study

Read the detailed description

This is a phase 3, multicenter, open-label, long-term safety and tolerability study of 6 mg daily dose of plecanatide administered orally. Patients who are Study Completers or Eligible Screen Failures whose eligibility is confirmed at the end of their participation in the double-blind plecanatide studies SP304203-04 or SP304203-05 will be enrolled.

Beginning on Day 1, patients will take one (1) plecanatide 6.0 mg tablet in the clinic and thereafter every morning with approximately 240 mL (8 ounces) of liquid, with or without meals.

Safety and tolerability assessments and patients' self-assessment of disease severity will be performed according to the Schedule of Assessments.

Patients who discontinue early from the study will undergo an Early Withdrawal (EW) visit within 5 days after stopping study drug.

03

Conditions studied

  • Irritable Bowel Syndrome
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Patients with documented diagnosis of IBS-C who:

  • Completed plecanatide study SP304203-04 or SP304203-05, were compliant with the previous study's requirements, and did not experience any Serious Adverse Event (SAE) deemed related to study drug during the course of the previous study, OR
  • Failed screening in study SP304203-04 or SP304203-05 due to diary noncompliance (an exclusion in the core study) or due to an administrative reason and is allowed to enter this study by notification from Sponsor or delegate.

Key Exclusion Criteria:

  • Patient is unwilling or unable to: participate in the study for the required duration, understand and sign the form (ICF) and undergo all protocol related tests and procedures throughout the study.
  • Female patient of with a positive urine pregnancy test on Day 1.
  • Male and female patients of childbearing potential who do not agree to continue to use the method of used in the core double-blind plecanatide study for the duration of this clinical trial.
  • Patient has experienced a significant negative change in health status during the course of participation in the core double-blind plecanatide study or after completion of the study.
  • In the opinion of the Investigator or Medical Monitor, it is not in the patient's best interest to participate in the study. The reason(s) for the patient's exclusion must be specified.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,272 participants (actual)

Study arms

  • Experimental
    Plecanatide

    Plecanatide 6.0 mg tablets

    Drug: Plecanatide

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Related Adverse Events.

    Number of participants with adverse events with evidence to suggest a causal relationship between treatment and study drug.

    Time frame: up to 53 weeks

07

Results

Posted Aug 18, 2020

Participant flow

Eligible subjects with IBS-C from SP304203-04 (NCT02387359), SP304203-05 (NCT02493452), and SP304-20212 (NCT01722318), and subjects that did not previously participate in any plecanatide study, were enrolled.

Participant flow — Overall Study
MilestonePlecanatide
Started2272
Completed1842
Not completed430
Withdrew: Adverse event97
Withdrew: Death1
Withdrew: Lack of efficacy39
Withdrew: Lost to follow-up101
Withdrew: Non-compliance with study drug15
Withdrew: Physician decision6
Withdrew: Pregnancy6
Withdrew: Protocol violation18
Withdrew: Withdrawal by subject136
Withdrew: Non-compliance with visits6
Withdrew: Site closure4
Withdrew: Subject moved1

Outcome measures

PrimaryNumber of Participants With Treatment Related Adverse Events.

Number of participants with adverse events with evidence to suggest a causal relationship between treatment and study drug.

Time frame:
up to 53 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Related Adverse Events.
ParticipantsPlecanatide
Number of Participants With Treatment Related Adverse Events.205

Adverse events

Collected over Up to 53 weeks.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Plecanatide1/2,272 (0%)45/2,272 (2%)341/2,272 (15%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventPlecanatide
Alanine Aminotransferase IncreasedInvestigations6/2272
Aspartate Aminotransferase IncreasedInvestigations5/2272
DiverticulitisInfections and infestations3/2272
Road Traffic AccidentInjury, poisoning and procedural complications2/2272
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders2/2272
Non-Cardiac Chest PainGeneral disorders2/2272
Liver Function Test AbnormalInvestigations1/2272
Transaminases IncreasedInvestigations1/2272
Bacterial PyelonephritisInfections and infestations1/2272
CellulitisInfections and infestations1/2272
Most frequent other events
Most frequent other events
EventPlecanatide
DiarrhoeaGastrointestinal disorders153/2272
Upper Respiratory Tract InfectionInfections and infestations43/2272
Urinary Tract InfectionInfections and infestations34/2272
NasopharyngitisInfections and infestations34/2272
NauseaGastrointestinal disorders29/2272
HeadacheNervous system disorders25/2272
SinusitisInfections and infestations23/2272

Baseline characteristics

Age, Continuous
Age, Continuous(years)Plecanatide
Mean45.3 ± 14.18
Sex: Female, Male
Sex: Female, Male(Participants)Plecanatide
Female1744
Male528
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Plecanatide
American Indian or Alaska Native4
Asian55
Native Hawaiian or Other Pacific Islander4
Black or African American504
White1692
More than one race13
Unknown or Not Reported0
Body Mass Index
Body Mass Index(kilograms per meters squared)Plecanatide
Mean28.4 ± 4.87
08

Study locations

204 sites
  • Synergy Research Site
    Athens, Alabama, United States
  • Synergy Research Site
    Birmingham, Alabama, United States
  • Synergy Research Site
    Dothan, Alabama, United States
  • Synergy Research Site
    Foley, Alabama, United States
  • Synergy Research Site
    Guntersville, Alabama, United States
  • Synergy Research Site
    Huntsville, Alabama, United States
  • Synergy Research Site
    Saraland, Alabama, United States
  • Synergy Research Site
    Chandler, Arizona, United States
  • Synergy Research Site
    Phoenix, Arizona, United States
  • Synergy Research Site
    Surprise, Arizona, United States
  • Synergy Research Site
    Tucson, Arizona, United States
  • Synergy Research Site
    Conway, Arkansas, United States
  • Synergy Research Site
    Glendale, Arkansas, United States
  • Synergy Research Site
    Little Rock, Arkansas, United States
  • Synergy Research Site
    Artesia, California, United States
  • Synergy Research Site
    Canoga Park, California, United States
  • Synergy Research Site
    Carmichael, California, United States
  • Synergy Research Site
    Chula Vista, California, United States
  • Synergy Research Site
    Corona, California, United States
  • Synergy Research Site
    Costa Mesa, California, United States
  • Synergy Research Site
    El Cajon, California, United States
  • Synergy Research Site
    Encino, California, United States
  • Synergy Research Site
    Foothill Ranch, California, United States
  • Synergy Research Site
    Fountain Valley, California, United States
  • Synergy Research Site
    Garden Grove, California, United States
  • Synergy Research Site
    Huntington Beach, California, United States
  • Synergy Research Site
    La Mesa, California, United States
  • Synergy Research Site
    La Mirada, California, United States
  • Synergy Research Site
    Laguna Hills, California, United States
  • Synergy Research Site
    Lancaster, California, United States
  • Synergy Research Site
    Lomita, California, United States
  • Synergy Research Site
    Long Beach, California, United States
  • Synergy Research Site
    Los Angeles, California, United States
  • Synergy Research Site
    North Hollywood, California, United States
  • Synergy Research Site
    Northridge, California, United States
  • Synergy Research Site
    Orange, California, United States
  • Synergy Research Site
    Placentia, California, United States
  • Synergy Research Site
    Riverside, California, United States
  • Synergy Research Site
    San Bernardino, California, United States
  • Synergy Research Site
    San Diego, California, United States
  • Synergy Research Site
    San Marino, California, United States
  • Synergy Research Site
    Sherman Oaks, California, United States
  • Synergy Research Site
    Thousand Oaks, California, United States
  • Synergy Research Site
    Colorado Springs, Colorado, United States
  • Synergy Research Site
    Denver, Colorado, United States
  • Synergy Research Site
    Lafayette, Colorado, United States
  • Synergy Research Site
    Bristol, Connecticut, United States
  • Synergy Research Site
    Hamden, Connecticut, United States
  • Synergy Research Site
    Atlantis, Florida, United States
  • Synergy Research Site
    Boca Raton, Florida, United States
  • Synergy Research Site
    Boynton Beach, Florida, United States
  • Synergy Research Site
    Bradenton, Florida, United States
  • Synergy Research Site
    Brandon, Florida, United States
  • Synergy Research Site
    Brooksville, Florida, United States
  • Synergy Research Site
    Clearwater, Florida, United States
  • Synergy Research Site
    Cutler Bay, Florida, United States
  • Synergy Research Site
    DeLand, Florida, United States
  • Synergy Research Site
    Fort Lauderdale, Florida, United States
  • Synergy Research Site
    Hialeah, Florida, United States
  • Synergy Research Site
    Homestead, Florida, United States
  • Synergy Research Site
    Inverness, Florida, United States
  • Synergy Research Site
    Jacksonville, Florida, United States
  • Synergy Research Site
    Lauderdale Lakes, Florida, United States
  • Synergy Research Site
    Miami Lakes, Florida, United States
  • Synergy Research Site
    Miami Springs, Florida, United States
  • Synergy Research Site
    Miami, Florida, United States
  • Synergy Research Site
    Naples, Florida, United States
  • Synergy Research Site
    North Miami Beach, Florida, United States
  • Synergy Research Site
    Orange Park, Florida, United States
  • Synergy Research Site
    Orlando, Florida, United States
  • Synergy Research Site
    Ormond Beach, Florida, United States
  • Synergy Research Site
    Oviedo, Florida, United States
  • Synergy Research Site
    Pembroke Pines, Florida, United States
  • Synergy Research Site
    Pinellas Park, Florida, United States
  • Synergy Research Site
    Port Orange, Florida, United States
  • Synergy Research Site
    Saint Petersburg, Florida, United States
  • Synergy Research Site
    Tamarac, Florida, United States
  • Synergy Research Site
    Tampa, Florida, United States
  • Synergy Research Site
    Atlanta, Georgia, United States
  • Synergy Research Site
    Marietta, Georgia, United States
  • Synergy Research Site
    Snellville, Georgia, United States
  • Synergy Research Site
    Blackfoot, Idaho, United States
  • Synergy Research Site
    Boise, Idaho, United States
  • Synergy Research Site
    Meridian, Idaho, United States
  • Synergy Research Site
    Blue Island, Illinois, United States
  • Synergy Research Site
    Chicago, Illinois, United States
  • Synergy Research Site
    Evanston, Illinois, United States
  • Synergy Research Site
    Evergreen Park, Illinois, United States
  • Synergy Research Site
    Hoffman Estates, Illinois, United States
  • Synergy Research Site
    Morton, Illinois, United States
  • Synergy Research Site
    Oak Lawn, Illinois, United States
  • Synergy Research Site
    Schaumburg, Illinois, United States
  • Synergy Research Site
    Brownsburg, Indiana, United States
  • Synergy Research Site
    Indianapolis, Indiana, United States
  • Synergy Research Site
    Topeka, Kansas, United States
  • Synergy Research Site
    Wichita, Kansas, United States
  • Synergy Research Site
    Madisonville, Kentucky, United States
  • Synergy Research Site
    Owensboro, Kentucky, United States
  • Synergy Research Site
    Baton Rouge, Louisiana, United States
  • Synergy Research Site
    Crowley, Louisiana, United States

Showing the first 100 of 204 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Barish CF, Crozier RA, Griffin PH. Long-term treatment with plecanatide was safe and tolerable in patients with irritable bowel syndrome with constipation. Curr Med Res Opin. 2019 Jan;35(1):81-85. doi: 10.1080/03007995.2018.1527303. Epub 2018 Oct 9. PubMed 30277094 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2016, a primary completion of May 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2020, 3 years 3 months after primary completion. A results delay was requested in May 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 29, 2016
First posted
Mar 11, 2016
Start
Jan 2016
Primary completionActual
May 2017
CompletionActual
Jun 2017
Results delay requested
May 23, 2019
Results first posted
Aug 18, 2020
Last update
Aug 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02706483
Responsible party
Sponsor
First posted
Mar 11, 2016
Start date
Jan 2016
Primary completion
May 2017
Completion
Jun 2017
Results posted
Aug 18, 2020
Last update
Aug 18, 2020

Study contacts

Angela Bulawski
study director · Bausch Health

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Plecanatide

Start the discussion